Literature DB >> 15640149

Engineering of a recombinant vitamin K-dependent gamma-carboxylation system with enhanced gamma-carboxyglutamic acid forming capacity: evidence for a functional CXXC redox center in the system.

Nadeem Wajih1, David C Sane, Susan M Hutson, Reidar Wallin.   

Abstract

The vitamin K-dependent gamma-carboxylation system in the endoplasmic reticulum membrane responsible for gamma-carboxyglutamic acid modification of vitamin K-dependent proteins includes gamma-carboxylase and vitamin K 2,3-epoxide reductase (VKOR). An understanding of the mechanism by which this system works at the molecular level has been hampered by the difficulty of identifying VKOR involved in warfarin sensitive reduction of vitamin K 2,3-epoxide to reduced vitamin K(1)H(2), the gamma-carboxylase cofactor. Identification and cloning of VKORC1, a proposed subunit of a larger VKOR enzyme complex, have provided opportunities for new experimental approaches aimed at understanding the vitamin K-dependent gamma-carboxylation system. In this work we have engineered stably transfected baby hamster kidney cells containing gamma-carboxylase and VKORC1 cDNA constructs, respectively, and stably double transfected cells with the gamma-carboxylase and the VKORC1 cDNA constructs in a bicistronic vector. All engineered cells showed increased activities of the enzymes encoded by the cDNAs. However increased activity of the gamma-carboxylation system, where VKOR provides the reduced vitamin K(1)H(2) cofactor, was measured only in cells transfected with VKORC1 and the double transfected cells. The results show that VKOR is the rate-limiting step in the gamma-carboxylation system and demonstrate successful engineering of cells containing a recombinant vitamin K-dependent gamma-carboxylation system with enhanced capacity for gamma-carboxyglutamic acid modification. The proposed thioredoxin-like (132)CXXC(135) redox center in VKORC1 was tested by expressing the VKORC1 mutants Cys(132)/Ser and Cys(135)/Ser in BHK cells. Both of the expressed mutant proteins were inactive supporting the existence of a CXXC redox center in VKOR.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15640149     DOI: 10.1074/jbc.M413982200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  24 in total

1.  Mycobacterium tuberculosis vitamin K epoxide reductase homologue supports vitamin K-dependent carboxylation in mammalian cells.

Authors:  Jian-Ke Tie; Da-Yun Jin; Darrel W Stafford
Journal:  Antioxid Redox Signal       Date:  2011-11-22       Impact factor: 8.401

2.  siRNA silencing of calumenin enhances functional factor IX production.

Authors:  Nadeem Wajih; Susan M Hutson; Reidar Wallin
Journal:  Blood       Date:  2006-08-10       Impact factor: 22.113

3.  Enhanced functional recombinant factor VII production by HEK 293 cells stably transfected with VKORC1 where the gamma-carboxylase inhibitor calumenin is stably suppressed by shRNA transfection.

Authors:  Nadeem Wajih; John Owen; Reidar Wallin
Journal:  Thromb Res       Date:  2008-01-03       Impact factor: 3.944

4.  Generation of hyperfunctional recombinant human factor IX variants expressed in human cell line SK-Hep-1.

Authors:  Aline Sousa Bomfim; Marcela Cristina Corrêa de Freitas; Virgínia Picanço Castro; Mario Abreu Soares Neto; Ricardo Pádua; Dimas Tadeu Covas; Elisa Maria Sousa Russo
Journal:  Biotechnol Lett       Date:  2020-11-01       Impact factor: 2.461

Review 5.  The oxidative protein folding machinery in plant cells.

Authors:  Isabel Aller; Andreas J Meyer
Journal:  Protoplasma       Date:  2012-10-23       Impact factor: 3.356

Review 6.  Understanding the pharmacogenetic approach to warfarin dosing.

Authors:  Ingrid Glurich; James K Burmester; Michael D Caldwell
Journal:  Heart Fail Rev       Date:  2008-11-08       Impact factor: 4.214

7.  A cellular system for quantitation of vitamin K cycle activity: structure-activity effects on vitamin K antagonism by warfarin metabolites.

Authors:  Jamil A Haque; Matthew G McDonald; John D Kulman; Allan E Rettie
Journal:  Blood       Date:  2013-12-02       Impact factor: 22.113

8.  VKORC1 pharmacogenomics summary.

Authors:  Ryan P Owen; Li Gong; Hersh Sagreiya; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2010-10       Impact factor: 2.089

9.  Glucuronidation of monohydroxylated warfarin metabolites by human liver microsomes and human recombinant UDP-glucuronosyltransferases.

Authors:  Agnieszka Zielinska; Cheryl F Lichti; Stacie Bratton; Neil C Mitchell; Anna Gallus-Zawada; Vi-Huyen Le; Moshe Finel; Grover P Miller; Anna Radominska-Pandya; Jeffery H Moran
Journal:  J Pharmacol Exp Ther       Date:  2007-10-05       Impact factor: 4.030

10.  Effects of the blood coagulation vitamin K as an inhibitor of arterial calcification.

Authors:  Reidar Wallin; Leon Schurgers; Nadeem Wajih
Journal:  Thromb Res       Date:  2008-01-30       Impact factor: 3.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.